Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecules and Cells

• Publication date

  2017-12-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molcel.2017.11.006PMID 29225033PMCID PMC6204219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62

  2016influential reference
• Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator

  2016cited by this paper
• Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer

  2015influential reference
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure

  2015influential reference
• A positive feedback loop between EBP2 and c-Myc regulates rDNA transcription, cell proliferation, and tumorigenesis

  2014influential reference
• Abstract 771: Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis.

  2013cited by this paper
• ChIP for identification of p53 responsive DNA promoters.

  2013cited by this paper
• Cdks, cyclins and CKIs: roles beyond cell cycle regulation

  2013cited by this paper
• HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

  2013cited by this paper
• Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo.

  2012cited by this paper
• MYC on the path to cancer.

  2012cited by this paper
• The role of mutant p53 in human cancer

  2011cited by this paper
• A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.

  2011influential reference
• Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

  2011cited by this paper
• Importazole, a small molecule inhibitor of the transport receptor importin-β.

  2011influential reference
• A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs.

  2010cited by this paper
• Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.

  2010influential reference
• The Hepatitis B Virus X Protein Modulates Hepatocyte Proliferation Pathways To Stimulate Viral Replication

  2010cited by this paper
• The Fbw7/Human CDC4 Tumor Suppressor Targets Proproliferative Factor KLF5 for Ubiquitination and Degradation through Multiple Phosphodegron Motifs*

  2010cited by this paper
• Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.

  2010cited by this paper
• Cell cycle, CDKs and cancer: a changing paradigm

  2009cited by this paper
• Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance

  2009cited by this paper
• The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.

  2009influential reference
• When mutants gain new powers: news from the mutant p53 field

  2009influential reference
• Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.

  2008cited by this paper
• Mycophenolic Acid Activation of p53 Requires Ribosomal Proteins L5 and L11*

  2008cited by this paper
• Widespread microRNA repression by Myc contributes to tumorigenesis

  2008cited by this paper
• TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

  2007cited by this paper
• HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation.

  2007cited by this paper
• Pin1-HBx interaction: a step toward understanding the significance of hepatitis B virus genotypes in hepatocarcinogenesis.

  2007cited by this paper
• The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease

  2007cited by this paper
• Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis.

  2007cited by this paper
• Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway.

  2007cited by this paper
• PIN1, the cell cycle and cancer

  2007cited by this paper
• Inhibition of c‐Myc activity by ribosomal protein L11

  2007cited by this paper
• Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

  2006cited by this paper
• Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis

  2006influential reference
• c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I

  2005cited by this paper
• Transcriptional regulation and transformation by Myc proteins

  2005cited by this paper
• Accommodation and Repair of a UV Photoproduct in DNA at Different Rotational Settings on the Nucleosome Surface*

  2005cited by this paper
• Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7

  2004cited by this paper
• TP53 and liver carcinogenesis

  2003cited by this paper
• The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults

  2002cited by this paper
• The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response

  2002cited by this paper
• The point mutation of p53 gene exon7 in hepatocellular carcinoma from Anhui Province, a non HCC prevalent area in China.

  2002influential reference
• Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.

  2001cited by this paper
• A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.

  2001cited by this paper
• Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC

  2001cited by this paper
• Cyclins and cell cycle checkpoints.

  1999cited by this paper
• Control of cell proliferation by Myc.

  1998cited by this paper
• Sequencing of p53 mutation in established human hepatocellular carcinoma cell line of HHC4 and HHC15 in nude mice.

  1998cited by this paper
• Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutation in vivo

  1998cited by this paper
• The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro

  1997cited by this paper
• The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice

  1997cited by this paper
• Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases*

  1997cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Differential activation of myc gene family members in hepatic carcinogenesis by closely related hepatitis B viruses

  1993cited by this paper
• Oncogenic forms of p53 inhibit p53-regulated gene expression.

  1992cited by this paper
• Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa

  1991cited by this paper
• p53 mutation in hepatocellular carcinoma after aflatoxin exposure.

  1991cited by this paper
• Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

  1991influential reference
• Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice.

  1989cited by this paper

• Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING

  2026cites this paper
• Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope

  2026cites this paper
• CDK4/6 Inhibitors Suppress RB-Null Triple-Negative Breast Cancer by Inhibiting Mutant P53 Expression via RBM38 RNA-Binding Protein

  2025cites this paper
• The Central Role of Pin1 in Age-Related Cancer Signaling Pathways.

  2025cites this paper
• PDCD11 Stabilizes C‐MYC Oncoprotein by Hindering C‐MYC‐SKP2 Negative Feedback Loop to Facilitate Progression of p53‐Mutant Breast and Colon Malignancies

  2025cites this paper
• Tripartite motif-containing protein 26 promotes colorectal cancer growth by inactivating p53

  2025cites this paper
• OTUD7B is a new deubiquitinase targeting p53

  2025cites this paper
• CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer

  2025cites this paper
• p53 enhances elesclomol-Cu-induced cuproptosis in hepatocellular carcinoma via FDXR-mediated FDX1 upregulation

  2025cites this paper
• Cooperation Between Aflatoxin-Induced p53 Aberrations and Hepatitis B Virus in Hepatocellular Carcinoma

  2025cites this paper
• Deciphering TICRR's oncogenic landscape in pancreatic adenocarcinoma: molecular insights and clinical implications

  2025cites this paper
• Elevated serum hepatic transaminases in apical periodontitis individuals.

  2024cites this paper
• Tripartite motif-containing protein 26 promotes colorectal cancer growth by inactivating p53

  2024cites this paper
• Construction of a TP53 mutation-associated ceRNA network as prognostic biomarkers in hepatocellular carcinoma

  2024cites this paper
• USP33 Regulates DNA Damage Response and Carcinogenesis Through Deubiquitylating and Stabilising p53

  2024cites this paper
• The mechanisms of Pin1 as targets for cancer therapy

  2024cites this paper
• Regulation of lipid and serine metabolism by the oncogene c-Myc.

  2024cites this paper
• CDK4 inactivation balances resistance to apoptosis with heightened metabolic sensitivity in triple negative breast cancer cells

  2024cites this paper
• A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer

  2024cites this paper
• CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation‐Mediated c‐Myc Deubiquitylation to Facilitate Mutant TP53 Transcription

  2024cites this paper
• p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications

  2024cites this paper
• SAHA/5-AZA Enhances Acetylation and Degradation of mutp53, Upregulates p21 and Downregulates c-Myc and BRCA-1 in Pancreatic Cancer Cells

  2024cites this paper
• Working title: Molecular involvement of p53‐MDM2 interactome in gastrointestinal cancers

  2024cites this paper
• Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery

  2024cites this paper
• The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer

  2023cites this paper
• A common druggable signature of oncogenic CMYC, mutant KRAS and mutant p53 reveals functional redundancy and competition of the oncogenes in cancer

  2023cites this paper
• Beyond cell cycle regulation: the pleiotropic function of CDK4 in cancer.

  2023cites this paper
• p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis

  2023cites this paper
• Searching for new early detection markers of OED and oral SCC using oral liquid-based cytology

  2023cites this paper
• Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth

  2023cites this paper
• MYC in liver cancer: mechanisms and targeted therapy opportunities

  2023cites this paper
• Targeting mutant-p53 for cancer treatment: Are we there yet?

  2023cites this paper
• Sex-biased genome-editing effects of CRISPR-Cas9 across cancer cells dependent on p53 status

  2023cites this paper
• Major genomic mutations driving hepatocellular carcinoma

  2023cites this paper
• Maintaining Genome Integrity: Protein Kinases and Phosphatases Orchestrate the Balancing Act of DNA Double-Strand Breaks Repair in Cancer

  2023cites this paper
• TP53-dependent CRISPR-Cas9 sex bias across cancer types affects MYC, PIK3CA, and SUV39H1 mediated by factors including SOX9, FOXO4, and PRC1

  2023cites this paper
• Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells

  2023cites this paper
• p53 mutation and deletion contribute to tumor immune evasion

  2023influential citation
• P63 and P73 Activation in Cancers with p53 Mutation

  2022influential citation
• Complete Models of p53 Better Inform the Impact of Hotspot Mutations

  2022cites this paper
• TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk

  2022cites this paper
• c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway

  2022cites this paper
• Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.

  2022cites this paper
• p53: From Fundamental Biology to Clinical Applications in Cancer

  2022cites this paper
• Identification and validation of the role of c-Myc in head and neck squamous cell carcinoma

  2022cites this paper
• Gene Regulation by p53 in Human Cancer System

  2022cites this paper
• Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors

  2022cites this paper
• SSBP1 drives high fructose-induced glomerular podocyte ferroptosis via activating DNA-PK/p53 pathway

  2022cites this paper
• NAMPT Inhibitor and P73 Activator Represses P53 R175H Mutated HNSCC Cell Proliferation in a Synergistic Manner

  2022cites this paper
• DNTTIP1 is a Prognostic Biomarker Correlated With Immune Infiltrates in Hepatocellular Carcinoma: A Study Based on The Cancer Genome Atlas Data

  2022cites this paper
• Inactivation of tumor suppressor TAp63 by hepatitis B virus X protein in hepatocellular carcinoma

  2022cites this paper
• Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart

  2021cites this paper
• Transition and identification of pathological states in p53 dynamics for therapeutic intervention

  2021cites this paper
• Molecular characterization of long-term survivors of hepatocellular carcinoma

  2021cites this paper
• Bcl-2 Associated Athanogene 2 (BAG2) is Associated With Progression and Prognosis of Hepatocellular Carcinoma: A Bioinformatics-Based Analysis

  2021cites this paper
• Targeting Pin1 for Modulation of Cell Motility and Cancer Therapy

  2021cites this paper
• The Role of p53 Signaling in Colorectal Cancer

  2021cites this paper
• Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells—Relevance for Understanding (Germ Cell) Tumorigenesis

  2021cites this paper
• Lnc-GD2H Promotes Proliferation by Forming a Feedback Loop With c-Myc and Enhances Differentiation Through Interacting With NACA to Upregulate Myog in C2C12 Myoblasts

  2021cites this paper
• Nicotine promotes WRL68 cells proliferation due to the mutant p53 gain-of-function by activating CDK6-p53-RS-PIN1-STAT1 signaling pathway.

  2020cites this paper
• The Interaction between Mutp 53 and NF-κB in Tumor Development

  2020influential citation
• Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development

  2020cites this paper
• Combining Ramachandran plot and molecular dynamics simulation for structural-based variant classification: Using TP53 variants as model

  2020cites this paper
• BCL7C suppresses ovarian cancer growth by inactivating mutant p53

  2020cites this paper
• Identification and prognostic value of DLGAP5 in endometrial cancer

  2020cites this paper
• p53 functional loss, stemness and hepatocellular carcinoma

  2020cites this paper
• Mutant p53 in Cancer Progression and Targeted Therapies

  2020cites this paper
• Mapping the epigenomic and transcriptomic interplay during memory formation and recall in the hippocampal engram ensemble

  2020cites this paper
• RBM10, a New Regulator of p53

  2020cites this paper
• Metabolic Syndrome Instead of Aflatoxin-Related TP53 R249S Mutation as a Hepatocellular Carcinoma Risk Factor.

  2020cites this paper
• Gain-of-function mutant p53 in cancer progression and therapy

  2020cites this paper
• Inactivating p53 is essential for nerve growth factor receptor to promote melanoma-initiating cell-stemmed tumorigenesis

  2020cites this paper
• The Janus Face of p53-Targeting Ubiquitin Ligases

  2020cites this paper
• A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer

  2020cites this paper
• Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma

  2020cites this paper
• Prolyl Isomerase Pin1 in Human Cancer: Function, Mechanism, and Significance

  2020cites this paper
• Function of PIN1 in Cancer Development and Its Inhibitors as Cancer Therapeutics

  2020cites this paper
• Crotonylation at serine 46 impairs p53 activity.

  2020cites this paper
• Codon 249 P53 Gene Mutation Among Hepatocellular Carcinoma Patients in Western Kenya

  2020cites this paper
• Metabolic Pathways Enhancement Confers Poor Prognosis in p53 Exon Mutant Hepatocellular Carcinoma

  2020cites this paper
• The Effect of a Newly Synthesized Ferrocene Derivative AGAINST MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway.

  2020cites this paper
• Oncogenic Hijacking of the PIN1 Signaling Network

  2019cites this paper
• Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a molecular target in breast cancer: a therapeutic perspective of gynecological cancer

  2019cites this paper
• It takes a team: a gain-of-function story of p53-R249S

  2019influential citation
• Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells.

  2019cites this paper
• Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells

  2019cites this paper
• Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53

  2019cites this paper
• Shrimp miRNA suppresses the stemness of human cancer stem cells via the PIN1 pathway

  2019cites this paper
• p53 modifications: exquisite decorations of the powerful guardian

  2019cites this paper
• Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences

  2019cites this paper
• Discovery of 4,6-bis(benzyloxy)-3-phenylbenzofuran as a novel Pin1 inhibitor to suppress hepatocellular carcinoma via upregulating microRNA biogenesis.

  2019cites this paper
• Role of cyclin‐dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway

  2019cites this paper
• PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell–like Traits and Multiple Biomarkers

  2019cites this paper
• Monocytes undergo multi-step differentiation in mice during oral infection by Toxoplasma gondii

  2019cites this paper
• Prolyl isomerase Pin1: a promoter of cancer and a target for therapy

  2018cites this paper
• Aberrant expression of ETS1 and ETS2 proteins in cancer.

  2018cites this paper
• Chromatin, nuclear lamins, and maintenance of the differentiated identity

  2018cites this paper
• Mutant p53 in cancer therapy—the barrier or the path

  2018cites this paper
• Tumor suppressor p53 and metabolism

  2018cites this paper
• Mutant p53 as a guardian of the cancer cell

  2018cites this paper